ClinicalTrials.gg
RecruitingNCT07659782TARGET-D 202Updated Nov 17, 2026

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

A Phase 2 interventional study of VS-7375 in Non-Small Cell Lung Cancer, sponsored by Verastem, Inc.. Recruiting at 26 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Verastem, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Nov 17, 2026First sites in Puerto Rico and Belgium12 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 521 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Planned enrollment
1,030th of 2,998
105 · median 56
Started
2026
with 130 others
Phase 2
1,079 of 3,371
120 open now
Primary completion
2027-06
later than 399 of 892 live
Registered
3,323rd of 3,371
by date

Among the 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 1,030th largest by planned enrollment of the 2,998 interventional ones that give a count, is one of 131 that started in 2026, is one of 1,079 in phase 2, reaches primary completion later than 399 of the 892 other live ones, and was the 3,323rd registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

521 of the 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

516 more — sign in →

All 521 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of VS-7375 alone in patients with metastatic KRAS G12D-mutated Non-Small Cell Lung Cancer

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histopathology confirmed unresectable locally advanced or NSCLC
  • per 1.1
  • Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)
  • PS=0 or 1
  • Adequate organ function
  • Received prior treatment with a platinum-based chemotherapy regimen and an in the advanced, non-resectable setting.
  • Have documented disease progression during or following their most recent .

Patients with 2L/3L on stable or preferred dose:

  • Received at least 1 and no more than 2 prior systemic lines of therapy for advanced (in the unresectable locally advanced or metastatic setting) NSCLC.

Patients with 2L-4L with :

  • Received at least 1 and no more than 3 prior systemic lines of therapy for advanced (in the unresectable locally advanced or metastatic setting) NSCLC.
  • Have asymptomatic and untreated brain metastases
  • At least 1 untreated measurable brain lesion per v1.1 with a long axis ≥ 0.5 cm and ≤ 3 cm.

Exclusion criteria

Exclusion Criteria:

  • Have any other documented co-existing common RAS mutation(s)
  • Prior anti-cancer Tx within 4 weeks or drug-specific timeline within first treatment dose, whichever shorter
  • Major surgery within 4 weeks of first treatment dose
  • Radiation therapy (RT) within 1 week of first treatment dose
  • History of drug-induced Interstitial Lung Disease
  • Receipt of prior direct RAS inhibitor
  • Untreated or symptomatic
  • Receipt of strong inhibitor/inducer or CYP3A4 sensitive substrates with narrow therapeutic index within 14 days or drug-specific timeline within first treatment dose, whichever is shorter
  • Receipt of PPI or H2 blocker within 5 days
  • Inability to swallow oral medication
  • Other protocol-defined inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    VS-7375 Monotherapy 2L/3L

    2L/3L VS-7375 dose

    Drug: VS-7375

  • Experimental
    VS-7375 Monotherapy 2L/3L Preferred Dose

    2L/3L Preferred VS-7375 dose

    Drug: VS-7375

  • Experimental
    2L-4L with brain metastasis

    2L-4L VS-7375 dose

    Drug: VS-7375

Interventions

06

What researchers measure

Primary outcomes

  1. Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1

    Overall Response Rate per RECIST version 1.1, per blinded independent central review (BICR)

    Time frame: 6 months

  2. To characterize the safety and tolerability of VS-7375 monotherapy administered on a daily oral schedule in participants with KRAS G12D-mutated NSCLC

    Proportion/number of participants with AEs, TEAEs, TRAEs, SAEs, and dose interruptions/reductions and discontinuations

    Time frame: 6 months

Secondary outcomes

  1. Confirmed ORR per RECIST v1.1 assessed by BICR (primary) and Investigator (secondary) assessments

    To evaluate additional efficacy parameters of VS-7375 monotherapy administered on a daily oral schedule in participants with KRAS G12D-mutated NSCLC

    Time frame: 24 months

  2. Plasma Pharmacokinetics (PK) of VS-7375 and relevant metabolites, Cmax

    Maximum concentration (Cmax)

    Time frame: 20 weeks

  3. Plasma Pharmacokinetics (PK) of VS-7375 and relevant metabolites, AUC

    Area under plasma Concentration (AUC) 0 to t

    Time frame: 20 weeks

  4. To evaluate Pharmacodynamics (PD) and other relevant blood tumor markers specific to tumor type

    CA19-9, CEA, CA-125

    Time frame: Up to 2.5 years

  5. To assess the health-related quality of life and disease based on European Organization for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire Core module C30 (QLQ-C30)

    The EORTC QLQ-C30 is a validated questionnaire to assess the quality of life of non-small cell lung cancer patients

    Time frame: 24 months

  6. Time to next therapy

    To assess the interval between initiation of study treatment and initiation of subsequent treatment

    Time frame: 24 months

Other outcomes

  1. Imaging of tumor metabolism changes

    To assess tumor metabolism dynamics on FDG-PET/CT

    Time frame: 24 months

07

Study locations

26 of 26 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

11 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jun 2027, 11 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 11 months is below that.

Counting every sponsor, half of 1,046 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2026
First posted
Jun 22, 2026
StartActual
Jul 22, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
12 sites added, 1 site removed — first sites in Puerto Rico and Belgium
Show 12 added (7 United States, 3 Puerto Rico, 1 Australia, 1 Belgium)
  • BRCR Global- Tamarac · Tamarac, United States
  • BRCR Global- Yauco · Yauco, Puerto Rico
  • University of Utah · Salt Lake City, United States
  • BRCR Global- San Juan · San Juan, Puerto Rico
  • BRCR Global- Yauco · Yauco, Puerto Rico
  • University of Chicago · Chicago, United States
  • University of North Carolina at Chapel Hill · Chapel Hill, United States
  • HonorHealth Research Institute · Scottsdale, United States
  • BRCR Global - Coral Springs · Coral Springs, United States
  • University of Colorado Cancer Center · Aurora, United States
  • Monash Health · Clayton, Australia
  • CHU UCL Namur - Sainte-Elisabeth · Namur, Belgium
Show 1 removed
  • BRCR Global- Yauco · Yauco, Puerto Rico
across 9 updates, Sep 25, 2026 – Nov 17, 2026
Site contacts
Changed at 7 sites. See the sites
Show 7 sites
  • Moffit Cancer Centre · Tampa, United StatesContact t•••@moffitt.org · •••7363→S•••@moffitt.org · •••4673
  • Cedars-Sinai Medical Center · Los Angeles, United StatesContact s•••@cshs.org · •••0882→G•••@cshs.org
  • University of Colorado Cancer Center · Aurora, United StatesContact s•••@cuanschutz.edu · •••8883→s•••@cuanschutz.edu · •••6624
  • MD Anderson Cancer Center · Houston, United StatesContact T•••@mdanderson.org→A•••@mdanderson.org
  • Chris O'Brien Lifehouse · Camperdown, AustraliaContact person changed (no phone or email listed)
  • Macquarie University Hospital · Sydney, AustraliaContact person changed (no phone or email listed)
  • ICON Cancer Centre South Brisbane · Brisbane, AustraliaContact person changed (no phone or email listed)
across 5 updates, Sep 30, 2026 – Nov 13, 2026
Show all 11 updates
  1. Nov 17, 2026
    1 site added — first site in Belgium
    Show site
    • CHU UCL Namur - Sainte-Elisabeth · Namur, Belgium
  2. Nov 13, 2026
    1 site added
    Show site
    • Monash Health · Clayton, Australia
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Chris O'Brien Lifehouse · Camperdown, AustraliaContact person changed (no phone or email listed)
    • Macquarie University Hospital · Sydney, AustraliaContact person changed (no phone or email listed)
    • ICON Cancer Centre South Brisbane · Brisbane, AustraliaContact person changed (no phone or email listed)
    + 1 other change: description
  3. Nov 6, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • MD Anderson Cancer Center · Houston, United StatesContact T•••@mdanderson.org→A•••@mdanderson.org
  4. Nov 4, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of Colorado Cancer Center · Aurora, United StatesContact s•••@cuanschutz.edu · •••8883→s•••@cuanschutz.edu · •••6624
  5. Oct 23, 2026
    1 site added
    Show site
    • University of Colorado Cancer Center · Aurora, United States
  6. Oct 19, 2026
    1 site added
    Show site
    • BRCR Global - Coral Springs · Coral Springs, United States
  7. Oct 15, 2026
    1 site added
    Show site
    • HonorHealth Research Institute · Scottsdale, United States
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Cedars-Sinai Medical Center · Los Angeles, United StatesContact s•••@cshs.org · •••0882→G•••@cshs.org
  8. Oct 14, 2026
    2 sites added
    Show 2 added (2 United States)
    • University of Chicago · Chicago, United States
    • University of North Carolina at Chapel Hill · Chapel Hill, United States
  9. Oct 7, 2026
    3 sites added, 1 site removed
    Show 3 added (2 Puerto Rico, 1 United States)
    • University of Utah · Salt Lake City, United States
    • BRCR Global- San Juan · San Juan, Puerto Rico
    • BRCR Global- Yauco · Yauco, Puerto Rico
    Show 1 removed
    • BRCR Global- Yauco · Yauco, Puerto Rico
  10. Sep 30, 2026
    1 site added — first site in Puerto Rico
    Show site
    • BRCR Global- Yauco · Yauco, Puerto Rico
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Moffit Cancer Centre · Tampa, United StatesContact t•••@moffitt.org · •••7363→S•••@moffitt.org · •••4673
  11. Sep 25, 2026
    1 site added
    Show site
    • BRCR Global- Tamarac · Tamarac, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07659782
Lead sponsor
Verastem, Inc.
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Jul 22, 2026
Primary completion
Jun 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Verastem Call Center
Contact
VS-7375-202TrialSupport@verastem.com
7812924204

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KRAS G12D Inhibitor VS-7375

Start the discussion